Background/Objectives: Acute kidney injury (AKI) is a frequent and serious complication following left ventricular assist device (LVAD) implantation. This study aimed to predict AKI within 90 days post-LVAD by evaluating urinary levels of vitamin D binding protein (VDBP) and kidney injury molecule-1 (KIM-1). Methods: We prospectively enrolled 29 advanced heart failure patients undergoing LVAD implantation and categorized them into four groups based on pre-LVAD kidney function and hemodynamic stability. Early-morning urine samples were collected 24 h before and 1 week after surgery. Urinary VDBP and KIM-1 levels, normalized to creatinine, were measured. Results: Thirteen patients developed AKI postoperatively. Both biomarkers were significantly elevated in patients with pre-existing kidney dysfunction and hemodynamic instability, as well as in those who developed AKI. Pre-LVAD VDBP and KIM-1 levels were associated with a nearly two-fold increased AKI risk. After adjusting for kidney function and hemodynamic status, this risk rose to 776% for KIM-1 and 674% for VDBP. Conclusions: Urinary VDBP and KIM-1 are promising non-invasive biomarkers for predicting AKI in LVAD patients. The predictive performance can be greatly improved after combining with pre-LVAD kidney function and hemodynamic stability. Early measurement may help identify high-risk individuals and guide perioperative management.
Vascular endothelial cadherin (VE-Cadherin) is a major endothelial adhesion molecule and can be cleaved explicitly by metalloproteinase domain-containing protein 10 (ADAM10). Vascular hyperpermeability may contribute to a greater susceptibility to sepsis in left ventricular assist device (LVAD) support patients. We aim to evaluate the efficacy of VE-Cadherin and ADAM10 for predicting sepsis in LVAD patients. We prospectively recruited 50 patients with advanced heart failure receiving LVAD therapy. Baseline and weekly postoperative blood samples (weeks 1–4) were collected, and plasma VE-cadherin and ADAM10 levels were measured. Sepsis occurred in 9 of 50 patients (18.0%). Across all sampling points, plasma VE-cadherin and ADAM10 levels were significantly higher in the sepsis group relative to the non-sepsis group. From pre-implantation to 1-week and 1-month post-operation, VE-Cadherin alone showed good performance for sepsis prediction, with areas under the receiver operating characteristic (AUC) of 0.75, 0.81, 0.69, 0.72, and 0.77, respectively. A significant positive correlation between VE-cadherin and ADAM10 was detected only among sepsis patients. Incorporating ADAM10 into the prediction models significantly enhances their predictive performance. Plasma VE-Cadherin levels can be a valuable biomarker for predicting sepsis in LVAD patients, with predictive performance further enhanced when combined with circulating ADAM10 levels.